Drug Trial Radar · NCT05551013
Treatment of Recurrent GBM With APG-157 Via Expanded Access
Last checked: Nov 19, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
No longer available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Aveta Biomics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2022
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 18 years, up to 85 years
Summary
As written by the sponsor on the registry.
This expanded access request will evaluate APG-157, a botanical drug under development for other cancers, as potential treatment for recurrent Glioblastoma multiforme (GBM) patients.
Conditions
- Glioblastoma
- Glioblastoma Multiforme
Interventions
APG-157Drug
APG-157 is an orally administered drug encased in a hydrogel pastille. Arms: * Ongoing Stupp protocol (will receive concurrent TMZ + APG-157) * Progression post TMZ (will receive APG-157 only) * Ongoing Optune (will receive concurrent Optune + APG-157) * Progression post Optune (will receive APG-157 only)
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.